Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA, USA.
Nephrol Dial Transplant. 2011 Feb;26(2):739-41. doi: 10.1093/ndt/gfq658. Epub 2010 Oct 25.
Atypical hemolytic uremic syndrome (aHUS) is a complex complement-mediated disease that progresses to end-stage renal failure (ESRF) in 50% of cases. Dysregulation of the alternative pathway (AP) of the complement cascade manifests as microangiopathic anaemia and thrombocytopenia. Multiple genes in the AP have been implicated in disease pathogenesis. Here, we report the clinical presentation of an affected patient that was inconsistent with genotype-phenotype data for carriers of CD46 mutations. Tests of AP function in this patient suggested additional genetic factors, and in-depth studies revealed a de novo heterozygous deletion that creates a novel CFH/CFHR1 fusion protein.
非典型溶血性尿毒症综合征(aHUS)是一种复杂的补体介导疾病,50%的病例会进展为终末期肾衰竭(ESRF)。补体级联的替代途径(AP)失调表现为微血管病性贫血和血小板减少症。AP 中的多个基因与疾病发病机制有关。在这里,我们报告了一名受影响患者的临床表现,与 CD46 突变携带者的基因型-表型数据不一致。对该患者 AP 功能的检测提示存在其他遗传因素,深入研究发现了一个新的杂合性缺失,导致一种新型 CFH/CFHR1 融合蛋白的产生。